Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/491
Title: | Formation of Antihyperlipidemic Nano-Ezetimibe from Volatile Microemulsion Template for Enhanced Dissolution Profile | Authors: | Saleem M.A. Yasir Siddique M. Nazar M.F. Khan S.U.-D. Ahmad A. Khan R. Hussain S.Z. Mat Lazim A. Azfaralariff A. Mohamed, M |
Keywords: | Chemical stability;Dissolution;Drops;Light scattering;Microemulsions;Volatile organic compounds | Issue Date: | 14-Jul-2020 | Publisher: | American Chemical Society | Journal: | Langmuir | Abstract: | Nanostructures play an important role in targeting sparingly water-soluble drugs to specific sites. Because of the structural flexibility and stability, the use of template microemulsions (μEs) can produce functional nanopharmaceuticals of different sizes, shapes, and chemical properties. In this article, we report a new volatile oil-in-water (o/w) μE formulation comprising ethyl acetate/ethanol/brij-35/water to obtain the highly water-dispersible nanoparticles of an antihyperlipidemic agent, ezetimibe (EZM-NPs), to enhance its dissolution profile. A pseudoternary phase diagram was delineated in a specified brij-35/ethanol ratio (1:1) to describe the transparent, optically isotropic domain of the as-formulated μE. The water-dilutable μE formulation, comprising an optimum composition of ethyl acetate (18.0%), ethanol (25.0%), brij-35 (25.0%), and water (32.0%), showed a good dissolvability of EZM around 4.8 wt % at pH 5.2. Electron micrographs showed a fine monomodal collection of EZM-loaded μE droplets (∼45 nm) that did not coalesce even after lyophilization, forming small spherical EZM-NPs (∼60 nm). However, the maturity of nanodrug droplets observed through dynamic light scattering suggests the affinity of EZM to the nonpolar microenvironment, which was further supported through peak-to-peak correlation of infrared analysis and fluorescence measurements. Moreover, the release profile of the as-obtained EZM-nanopowder increased significantly >98% in 30 min, which indicates that a reduced drug concentration will be needed for capsules or tablets in the future and can be simply incorporated into the multidosage formulation of EZM. |
Description: | Web of Science / Scopus |
URI: | http://hdl.handle.net/123456789/491 | ISSN: | 07437463 | DOI: | 10.1021/acs.langmuir.0c01016 |
Appears in Collections: | Faculty of Bioengineering and Technology - Journal (Scopus/WOS) |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.